在长期使用利妥昔单抗治疗后，较少频次的利妥昔单抗再治疗可维持视神经脊髓炎谱系障碍的缓解状态。 - Suppr

Suppr

超能文献

Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment.

作者信息

Kim Su-Hyun, Kim Yeseul, Kim Gayoung, Park Na Young, Jang Hyun-Min, Shin Hyun-June, Hyun Jae-Won, Kim Ho Jin

机构信息

Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, South Korea.

出版信息

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):486-487. doi: 10.1136/jnnp-2018-318465. Epub 2018 Jun 21.

DOI:10.1136/jnnp-2018-318465

PMID:29929977

Abstract

摘要

相似文献

Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment.在长期使用利妥昔单抗治疗后，较少频次的利妥昔单抗再治疗可维持视神经脊髓炎谱系障碍的缓解状态。

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):486-487. doi: 10.1136/jnnp-2018-318465. Epub 2018 Jun 21.

Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.利妥昔单抗治疗停止后视神经脊髓炎的长期缓解

J Child Neurol. 2015 Sep;30(10):1366-70. doi: 10.1177/0883073814553974. Epub 2014 Nov 10.

Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.监测利妥昔单抗治疗的视神经脊髓炎谱系障碍患者的CD27+记忆B细胞：一项双中心研究的结果

J Neurol Sci. 2017 Feb 15;373:335-338. doi: 10.1016/j.jns.2017.01.025. Epub 2017 Jan 10.

A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.20 例视神经脊髓炎谱系疾病患者接受利妥昔单抗治疗的长期随访。

Mult Scler Relat Disord. 2020 May;40:101933. doi: 10.1016/j.msard.2020.101933. Epub 2020 Jan 5.

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.视神经脊髓炎患者接受利妥昔单抗重复治疗后的长期随访。

Neurology. 2011 Apr 12;76(15):1310-5. doi: 10.1212/WNL.0b013e3182152881.

Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.在 AQP4-IgG 阳性视神经脊髓炎谱系疾病患者中，利妥昔单抗治疗后 B 细胞耗竭时间延长。

J Neuroimmunol. 2021 Sep 15;358:577666. doi: 10.1016/j.jneuroim.2021.577666. Epub 2021 Jul 18.

Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.利妥昔单抗治疗 100 例视神经脊髓炎患者的治疗结果：FCGR3A 多态性对利妥昔单抗治疗反应的影响。

JAMA Neurol. 2015 Sep;72(9):989-95. doi: 10.1001/jamaneurol.2015.1276.

Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.基于复发型视神经脊髓炎患者外周循环记忆B细胞评估进行利妥昔单抗重复治疗超过2年。

Arch Neurol. 2011 Nov;68(11):1412-20. doi: 10.1001/archneurol.2011.154. Epub 2011 Jul 11.

Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.使用维持治疗方案并密切监测 CD19 B 细胞，用利妥昔单抗治疗视神经脊髓炎和视神经脊髓炎谱系障碍。六年随访。

J Neurol Sci. 2017 Jan 15;372:92-96. doi: 10.1016/j.jns.2016.11.016. Epub 2016 Nov 10.

Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.视神经脊髓炎谱系疾病患者使用利妥昔单抗的长期耐受性、安全性和疗效：一项前瞻性研究。

J Neurol. 2019 Mar;266(3):642-650. doi: 10.1007/s00415-019-09180-9. Epub 2019 Jan 11.

引用本文的文献

Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD.视神经脊髓炎谱系疾病（NMOSD）中使用靶向B细胞的单克隆抗体治疗期间的复发情况。

J Neurol. 2025 May 18;272(6):406. doi: 10.1007/s00415-025-13118-9.

Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.利妥昔单抗治疗多发性硬化和视神经脊髓炎谱系疾病的疗效和安全性。

Sci Rep. 2024 Feb 12;14(1):3503. doi: 10.1038/s41598-024-53838-y.

Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.利妥昔单抗低剂量治疗视神经脊髓炎谱系疾病：一项多中心、开放标签、自身对照、前瞻性随访研究。

Front Immunol. 2023 Aug 8;14:1148632. doi: 10.3389/fimmu.2023.1148632. eCollection 2023.

Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?利妥昔单抗在多发性硬化症中的疗效超过 B 细胞再增殖：是否需要重新考虑剂量？

Neurol Neuroimmunol Neuroinflamm. 2023 Aug 21;10(5). doi: 10.1212/NXI.0000000000200152. Print 2023 Sep.

Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.利妥昔单抗降级治疗视神经脊髓炎谱系疾病患者。

Neurology. 2023 Jul 25;101(4):e438-e450. doi: 10.1212/WNL.0000000000207443. Epub 2023 Jun 8.

Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study.根据视神经脊髓炎谱系障碍和MOG相关疾病中CD27阳性B细胞与CD19阳性B细胞监测情况定制利妥昔单抗：一项单中心研究结果

Neurol Ther. 2023 Aug;12(4):1375-1383. doi: 10.1007/s40120-023-00481-w. Epub 2023 May 11.

Origins and immunopathogenesis of autoimmune central nervous system disorders.自身免疫性中枢神经系统疾病的起源和免疫发病机制。

Nat Rev Neurol. 2023 Mar;19(3):172-190. doi: 10.1038/s41582-023-00776-4. Epub 2023 Feb 14.

Effectiveness and Safety of Immunosuppressive Drug Therapy for Neuromyelitis Optica Spectrum Disorders: An Overview of Meta-Analyses and Systematic Reviews.视神经脊髓炎谱系疾病免疫抑制药物治疗的有效性和安全性：荟萃分析和系统评价概述。

Curr Neuropharmacol. 2023;21(8):1827-1834. doi: 10.2174/1570159X20666220922151442.

Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience.利妥昔单抗诱导的低丙种球蛋白血症与视神经脊髓炎谱系障碍感染风险：14 年真实世界经验。

Neurol Neuroimmunol Neuroinflamm. 2022 Jul 19;9(5). doi: 10.1212/NXI.0000000000001179. Print 2022 Sep.

Naïve B cells followed by aquaporin-4 antibodies characterise the onset of neuromyelitis optica: evidence from stem cell transplantation.初始B细胞继水通道蛋白4抗体之后出现是视神经脊髓炎发病的特征：来自干细胞移植的证据。

J Neurol Neurosurg Psychiatry. 2022 May 23;93(11):1234-6. doi: 10.1136/jnnp-2022-328982.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验